The First Affiliated Hospital of Shantou University Medical College
The First Affiliated Hospital of Shantou University Medical College
Shantou, Guangdong, China8 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patterns of Use in Real-world Practice | Genital Diseases, Urogenital Diseases, infertility disorder | Active, not recruiting | Not stated | 2026-09-25 | NCT07029451 | |
| Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Not stated | 2026-09-16 | NCT05457049 | |
| Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal cancer, rectal disorder, rectal neoplasm | Recruiting | Phase 2 | 2026-07-24 | NCT07104604 | |
| A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-07-23 | NCT05609370 | |
| A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2026-05-26 | NCT07375316 | |
| Efficacy and Safety of SR1375 in Adult Patients With CAP | Community-Acquired Infections, Community-Acquired Pneumonia, Infections, pneumonia, respiratory system disorder, respiratory tract infectious disorder | Recruiting | Phase 2 | 2025-07-09 | NCT06577558 | |
| Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock | Vasodilatory Shock | Recruiting | Phase 3 | 2025-01-23 | NCT06351150 | |
| Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System | cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Not yet recruiting | Not applicable | 2021-08-06 | NCT04995159 |